Toward the elimination of race-based medicine: replace race with racism as preeclampsia risk factor.

aspirin prophylaxis health inequities maternal morbidity and mortality obstetrical outcomes preeclampsia race-based medicine racism

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
10 2022
Historique:
received: 12 01 2022
revised: 17 05 2022
accepted: 23 05 2022
pubmed: 1 6 2022
medline: 5 10 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Pregnancy-related morbidity and mortality continue to disproportionately affect birthing people who identify as Black. The use of race-based risk factors in medicine exacerbates racial health inequities by insinuating a false conflation that fails to consider the underlying impact of racism. As we work toward health equity, we must remove race as a risk factor in our guidelines to address disparities due to racism. This includes the most recent US Preventive Services Taskforce, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine guidelines for aspirin prophylaxis in preeclampsia, where the risk factor for "Black race" should be replaced with "anti-Black racism." In this commentary, we reviewed the evidence that supports race as a sociopolitical construct and the health impacts of racism. We presented a call to action to remove racial determination in the guidelines for aspirin prophylaxis in preeclampsia and more broadly in our practice of medicine.

Identifiants

pubmed: 35640703
pii: S0002-9378(22)00413-6
doi: 10.1016/j.ajog.2022.05.048
pii:
doi:

Substances chimiques

Aspirin R16CO5Y76E

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

593-596

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Erinma P Ukoha (EP)

Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA; Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY. Electronic address: erinmapukoha@gmail.com.

Michael E Snavely (ME)

Family and Community Medicine, University of California, San Francisco, San Francisco, CA.

Monica U Hahn (MU)

Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA; Family and Community Medicine, University of California, San Francisco, San Francisco, CA.

Jody E Steinauer (JE)

Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA.

Allison S Bryant (AS)

Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH